Intrathecal treatment with anti-Nogo-A antibody improves functional recovery in adult rats after stroke.
Stroke often results in devastating neurological disabilities with no specific treatment available to improve functional recovery. Neurite growth inhibitory proteins such as Nogo-A play a critical role in impeding regain of function after stroke. We have reported that treatment with anti-Nogo-A antibody using the intracerebroventricular route resulted in improvement of function and neuroplasticity in adult or aged rats after stroke. This present study tested a more clinically accessible route for applying anti-Nogo-A antibodies, the intrathecal route. Anti-Nogo-A or control antibody was administered intrathecally at lower lumbar levels 1 week after middle cerebral artery occlusion in adult rats. Our results show that anti-Nogo-A antibody delivered by this intrathecal route for 2 weeks penetrated into brain parenchyma and bound to myelin-enriched structures such as the corpus callosum and striatal white matter. Animals receiving anti-Nogo-A antibody treatment significantly improved recovery of function on the skilled forelimb reaching task as compared to stroke only and stroke/control antibody animals. These findings show that anti-Nogo-A antibody delivered through the intrathecal route is as effective in restoring lost functions after stroke as the intracerebroventricular route. This is of great importance for the future application of anti-Nogo-A immunotherapy for ischemic stroke treatment.
Tsai
Shih-Yen
SY
Neurology and Research Service, Hines VA Hospital, Roosevelt Road and Fifth Avenue, Hines, IL 60141, USA. shih-yen.tsai@va.gov
Markus
Tiffanie M
TM
Andrews
Ellen M
EM
Cheatwood
Joseph L
JL
Emerick
April J
AJ
Mir
Anis K
AK
Schwab
Martin E
ME
Kartje
Gwendolyn L
GL
D000704:Analysis of Variance; D000818:Animals; D000906:Antibodies / Q000008:administration & dosage*; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D004195:Disease Models, Animal; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy* / Q000473:pathology; D007278:Injections, Spinal / Q000379:methods; D008297:Male; D009185:Myelin Proteins / Q000276:immunology*; D000070798:Nogo Proteins; D011597:Psychomotor Performance / Q000187:drug effects; D051381:Rats; D020318:Rats, Long-Evans; D020127:Recovery of Function / Q000187:drug effects*; D013116:Spinal Cord / Q000187:drug effects / Q000378:metabolism; D013997:Time Factors
D000906:Antibodies; D009185:Myelin Proteins; D000070798:Nogo Proteins; C000603197:Rtn4 protein, rat
Ann Neurol. 1999 Jun;45(6):778-86
10360770
Pediatr Neurol. 2006 Jan;34(1):1-6
16376270
J Neurosci. 2002 Jul 1;22(13):5505-15
12097502
Nature. 1980 Mar 20;284(5753):264-5
7360259
J Neurosci. 2002 May 1;22(9):3553-67
11978832
Nat Med. 2006 Jul;12 (7):790-2
16819551
Curr Pain Headache Rep. 2006 Feb;10(1):26-33
16499827
Clin Cancer Res. 2001 Jul;7(7):2050-6
11448923
J Comp Neurol. 1999 Jul 19;410(1):143-57
10397401
Neuron. 1994 Sep;13(3):757-67
7522484
Neuropharmacology. 2006 Jun;50(7):777-87
16469338
Behav Brain Res. 2005 Jul 1;162(1):71-82
15922067
J Cereb Blood Flow Metab. 2005 Oct;25(10 ):1366-75
15889044
Cerebrospinal Fluid Res. 2005 Sep 20;2:6
16174293
Neuron. 1994 Oct;13(4):805-11
7524558
Science. 1981 Nov 20;214(4523):931-3
6171034
Ann Neurol. 2002 Apr;51(4):433-41
11921049
J Cereb Blood Flow Metab. 2003 Feb;23 (2):154-65
12571447
J Neurosci. 2004 Jul 7;24(27):6209-17
15240813
Brain Res. 1991 Apr 5;545(1-2):103-13
1713524
Exp Eye Res. 1999 Mar;68(3):303-11
10079138
Brain Res. 2002 Mar 15;930(1-2):67-74
11879797
Ann Neurol. 2005 Nov;58(5):706-19
16173073
Mol Cell Neurosci. 2006 May-Jun;32(1-2):161-73
16697217
Behav Brain Res. 2006 Dec 15;175(2):249-62
17049628
Cereb Cortex. 2006 Apr;16(4):529-36
16033928
Eur J Neurosci. 2004 Nov;20(9):2479-82
15525289
Brain Res. 1985 Feb 4;326(1):47-63
3971148
J Neurosci. 2001 Jul 15;21(14):5272-80
11438602
J Neurosci. 2003 Jun 15;23 (12 ):4826-30
12832504
Curr Opin Neurobiol. 2004 Feb;14 (1):118-24
15018947
Mol Cell Neurosci. 2004 Oct;27(2):163-74
15485772
Ann Neurol. 2005 Dec;58(6):950-3
16315284